Your browser doesn't support javascript.
loading
In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.
Vassilakopoulou, Maria; Togun, Taiwo; Dafni, Urania; Cheng, Huan; Bordeaux, Jennifer; Neumeister, Veronique M; Bobos, Mattheos; Pentheroudakis, George; Skarlos, Dimosthenis V; Pectasides, Dimitrios; Kotoula, Vassiliki; Fountzilas, George; Rimm, David L; Psyrri, Amanda.
Afiliación
  • Vassilakopoulou M; Yale University, School of Medicine, Department of Pathology, New Haven, Connecticut, United States of America.
  • Togun T; Yale University, School of Public Health, Department of Biostatistics, New Haven, Connecticut, United States of America.
  • Dafni U; Laboratory of Biostatistics, University of Athens School of Nursing, Athens, Greece.
  • Cheng H; Yale University, School of Medicine, Department of Pathology, New Haven, Connecticut, United States of America.
  • Bordeaux J; Yale University, School of Medicine, Department of Pathology, New Haven, Connecticut, United States of America.
  • Neumeister VM; Yale University, School of Medicine, Department of Pathology, New Haven, Connecticut, United States of America.
  • Bobos M; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
  • Pentheroudakis G; Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece.
  • Skarlos DV; Second Department of Medical Oncology, "Metropolitan" Hospital, Piraeus, Greece.
  • Pectasides D; Oncology Section, Second Department of Internal Medicine, "Hippokration" Hospital, Athens, Greece.
  • Kotoula V; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
  • Fountzilas G; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Department of Medical Oncology, "Papageorgiou" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
  • Rimm DL; Yale University, School of Medicine, Department of Pathology, New Haven, Connecticut, United States of America.
  • Psyrri A; Division of Oncology, Second Department of Internal Medicine, University of Athens School of Medicine, Attikon University Hospital, Athens, Greece.
PLoS One ; 9(6): e99131, 2014.
Article en En | MEDLINE | ID: mdl-24968015
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / ARN Mensajero / Biomarcadores de Tumor / Receptor ErbB-2 / Anticuerpos Monoclonales Humanizados / Antineoplásicos Tipo de estudio: Etiology_studies / Evaluation_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / ARN Mensajero / Biomarcadores de Tumor / Receptor ErbB-2 / Anticuerpos Monoclonales Humanizados / Antineoplásicos Tipo de estudio: Etiology_studies / Evaluation_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos